Anti-Proliferative and Apoptotic Effects of Polygonum Cuspidatum and its Bioactive Compound, Emodin, in Colorectal Carcinoma HT-29 cells

Pin Der Duh¹, Tsuey Pin Lin², Shu Ching Huang², Shih Ying Chen²*, Chin Chen Chu³,⁴, Jen Yin Chen⁵, Chin Hui Chen⁶

¹ Department of Food Science and Technology, Chia Nan University of Pharmacy and Science, Tainan, Taiwan, ROC
² Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan, ROC
³ Department of Anesthesiology, Chi-Mei Medical Center, Tainan, Taiwan, ROC
⁴ Department of Recreation and Healthcare Management, Chia Nan University of Pharmacy and Science Tainan, Taiwan, R.O.C
⁵ Department of Senior Citizen Service Management, Chia Nan University of Pharmacy and Science Tainan, Taiwan, R.O.C
⁶ Department of Health Leisure and Management, Yuanpei University of Science and Technology, HsinChu, Taiwan, ROC

Abstract
Antiproliferative and apoptotic effects of ethyl acetate from the root of Polygonum cuspidatum (EAPC) and its bioactive compound, emodin, in colorectal adenocarcinoma HT-29 cells were investigated. HPLC analysis of major compounds, cell viability by MTT assay, the Comet assay, determination of reactive oxygen species (ROS) levels, apoptosis assay by flow cytometry and Western blot analysis were conducted. The results show significant antiproliferative effects of EAPC, IC₅₀=141.4 μg/mL, and emodin isolated from EAPC, IC₅₀=73.0 μg/mL, on HT-29 cells. HT-29 cells which were exposed to EAPC and emodin exerted apoptosis, after annexin V FITC/PI staining. EAPC (at 200 μg/mL) and emodin (at 100 μg/mL) increase DNA damage in HT-29 cells by 75.6% and 67.8%, respectively, supporting that apoptosis occurred when the cells were treated with EAPC and emodin. Cells treated with EAPC and emodin generated intracellular ROS. In addition, emodin at tested doses of 25-100 μg/mL suppressed nuclear factor κB (NFκB) and enhanced activator protein 1 (AP-1), which are involved in both proliferation and apoptosis events. EAPC and emodin demonstrated significant anti-proliferation of HT-29 cells through their pro-oxidant activity and contribution to oxidative stress, which in turn leads to cell death. EPAC and emodin inhibited HT-29 cell growth via apoptosis and could be considered as potential candidates for anti-colorectal cancer treatment.

Keywords: Antiproliferation; Apoptosis; Polygonum cuspidatum; Emodin; HT-29 cell

Introduction
Several epidemiological studies have provided convincing evidence that a large body of cancer-related deaths is closely linked to unhealthy diet and lifestyle. Nowadays cancer is a major public health issue throughout the world⁴. Cancer treatment depends on the type and stage of cancer, including surgery, radiotherapy, chemotherapy, hormone therapy, biological therapies, bisphosphonates, bone marrow, stem cell transplants, complementary and alternative therapies. However, different cancer treatments have produced different side effects, including nausea, pain and fatigue, which can make patients uncomfortable and affect their ability to stick to their treatments⁵. Among different types of cancer, colorectal cancer was the third leading cause of cancer-related cases in Taiwan and the second leading cause in the United States in 2014⁶. So far current treatment of colorectal cancer generally employs surgical resection combined with chemotherapy and radiation therapy⁷. However, this treatment is not fully successful for late stage colorectal cancer patients⁸. Consequently, search for novel and effective approaches to the treatment of this cancer is required. In addition, a number of studies have shown that high consumption of vegetables, fruits, photochemical and chemo preventive agents from natural products decreases the risk of colorectal cancer. Therefore, development of novel agents from plant-derived natural products can potentially provide a beneficial and valuable source for anti-colorectal cancer treatment.

Copyright: © 2018 Chen, S. This is an Open access article distributed under the terms of Creative Commons Attribution 4.0 International License.

DOI: 10.15436/2377-0619.18.1731
**Polygonum cuspidatum** has been conventionally used as folk medicines in many countries for centuries. Traditionally, *Polygonum cuspidatum* has been used for the treatment of serious diseases such as asthma, cough, hypertension, and cancer\(^4\). The biological activity of *Polygonum cuspidatum* has been reported. For example, the ethanolic extracts of *Polygonum cuspidatum* have been described as displaying biological activity, having the potential to inhibit hepatitis virus (HBV) replication\(^2\), and EBV lytic cycle\(^5\). In addition, this herb has been reported to contain many bioactive compounds such as anthraglycoside B, physcion, piceid, emodin and resveratrol. In addition, a previous study by the authors of this paper demonstrated that ethyl acetate sub fraction F3, extracted from *Polygonum cuspidatum*, and its major bioactive compound, emodin, exhibited significant inhibition of Epstein-Barr virus (EBV)\(^5\). Given that *Polygonum cuspidatum* can inhibit HBV and EBV, it may also have the potential to inhibit the proliferation of cancer cells. However, it remains unclear whether *Polygonum cuspidatum* exhibits an antiproliferative effect against cancer cells. Therefore, this study aims to determine the antiproliferative effect of *Polygonum cuspidatum* and its bioactive compound, emodin, on human colorectal carcinoma HT-29 cells and also to elucidate the possible mechanism action.

**Material and Methods**

**Material**

The root of *Polygonum cuspidatum* was collected from the San-Dei-Men area in Pingtung County, Taiwan and verified by Prof. C. S. Kuoh. The specimen was deposited in the herbarium of the National Cheng Kung University, Tainan, Taiwan.

**Sample Preparation:** Ten grams of dried powder from the *P. cuspidatum* root was extracted three times in 100 mL of ethanol by refluxing at 85 °C for 2 h. After each extraction, the ethanol fraction was collected by filtration. The ethanol fractions were partitioned twice with hexane and water (10:10:1, v/v/v). The aqueous fractions were collected, concentrated under reduced pressure, and called EPC. Dried EPC (1 g) dissolved in 100 mL distilled water was partitioned with an equal volume of ethyl acetate (EtOAc). The EtOAc fractions were collected, concentrated under reduced pressure, and called EAPC. The EAPC soluble fraction was subjected to semi-preparative HPLC using a HYPERPREP C18 (150 × 10 mm i.d., 8 μm) column (Thermo Fisher, Waltham, MA, USA) and eluted with a mobile phase consisting of water (A) and methanol (B) for emodin preparation. Gradient elution was performed as follows: 30%–50% B in 0–15 min, 50%–90% B in 15–35 min, and 95% B in 35–45 min. The resulting residues were finally dissolved in dimethyl sulfoxide (DMSO)\(^2\). The vehicle control in this study was necessary because test samples were dissolved in DMSO (final concentration was 0.5%).

**Identification by HPLC Analysis**

The components in the EAPC soluble fraction and separated emodin were further analyzed by high performance liquid chromatography (HPLC) using a Li Chrospher 100 RP-18e (250 × 4.6 mm i.d., 5 μm) column (Merck, Darmstadt, Germany). The mobile phase consisted of water (A) and methanol (B). Gradient elution was performed as follows: 30%–50% B in 0–15 min, 50%–90% B in 15–35 min, and 95% B in 35–45 min. The flow rate was set at 1 mL/min. The identification of piceid, resveratrol, anthraglycoside B and emodin was carried out by comparing their retention times and characteristic spectra with those of authentic standards (Figure 1).

![HPLC Chromatograms and UV Spectra of the Ethyl acetate Sub fraction isolated from Polygonum cuspidatum Root (A), Standard of Emodin (B) and Separated Emodin (C).](image)

**Note:** Mobile phase: methanol–water (methanol: 0–15 min, 30%–50%; 15–35 min, 50%–90%; 35–45 min, 95%); flow rate: 1.0 mL/min; detection wavelength: 280 nm.
The knowledge of the identity of the sample. Volumes of 10 μL of out under indirect light. Slides were coded and analyzed without late apoptosis methods of Szeto et al. and Braz et al.[4,1,27]. Each step was carried Comet assay was determined and modified by the methods of Szeto et al. and Braz et al.[4,1,27]. Each step was carried out under indirect light. Slides were coded and analyzed without knowledge of the identity of the sample. Volumes of 10 μL of cells (1 × 10^6 cells/mL) treated with 3-48 h were added to 0.5% low melting point agarose, respectively, at 37 °C. The mixtures were layered onto slides precoated with 1.5% normal agarose, covered with a cover slip, and left for 5 min at 4 °C to solidify the agarose. Afterwards, the cover slips were carefully removed and the slides immersed in a lysis solution for 15 min. Then, the slides were immersed in a freshly prepared alkaline buffer in a horizontal electrophoresis tank. After a 20 min DNA unwinding period, electrophoresis was conducted at 30 V and 300 mA for 20 min. Following 10 min neutralization with 0.4 M tris (hydroxymethyl) amino methane (Tris, pH 7.5), the slides were fixed in methanol, and stored at 4 °C. Before analysis, the slides were stained with 10 μL propidium iodide (2.5 μg/mL) and scored using a fluorescent microscope (Nikon, Tokyo, Japan) at 200 × magnifications. Images from 100 “nucleoids” (20-30 from each of two replicate slides per sample) were analyzed using the Comet assay free software (Perceptive Instruments, Haverhill, Su Volk, UK). Tail moment and tail intensity were used to estimate DNA damage. As tail intensity (% DNA tail) gave similar results, only tail moment values were presented.

Evaluation of Reactive Oxygen Species (ROS) in HT-29 Cells
Intracellular ROS was estimated by using a fluorescent probe, DCFH-DA[7]. To determine the generation of ROS in HT-29 cells, DCFH-DA was used when it penetrates the cell membranes and was hydrolyzed by intracellular esterase to form dichlorofluorescin (DCFH). HT-29 cells (5 × 10^6 cells/mL) were pretreated with DCFH-DA (50 μM) for 30 min, and then samples were added to the medium. After incubation at 37 °C for 3-48 h, ROS produced from intracellular stress was detected using a Bio-Tek FLX800 micro plate fluorescence reader (Fisher Scientific) with excitation and emission wavelengths of 480 and 530 nm, respectively.

Measurement of Caspase-3 Activity Determination
Activity of caspase-3 was determined by using fluorometric assay kits (Promega-Corporation, Madison, WI, USA) according to the manufacturer’s protocol. In brief, the cells (5×10^4 cells/mL) were plated in 24 well. After 24 h incubation; cells were treated with the test samples for 3-48 h. The cells were removed and added 25 μL Caspase-Glo® 3/7/kit. After incubation in 5% CO2/95% air at 37°C for 1 h, the activity was measured using a fluorophotometer (FLX 800, BioTek®) with luminol. Data were expressed as percentage of the control, and the control group was designed as 100%[7].

Preparation of Nuclear Extracts
Nuclear extracts from treated cells were prepared with a nuclear extract kit (Panomics Inc., Redwood City, CA, USA) according to the user manual. Protein concentrations were determined by the Bradford assay (Bio-Rad, Richmond, CA, USA). Briefly, HT-29 cells were washed with cold PBS for two times, scraped into PBS with 1 mM phenylmethylsulphonylfluoride (PMSF) and pelleted by centrifugation (500 g) at 4°C for 10 min. Cell pellets were resuspended in buffer A (20 mM HEPEs, pH 7.9, 10 mM KCl, 0.1 mM ethylenediamine tetra acetic acid (EDTA), 1 mM ethyleneglycol tetra acetic acid (EGTA), 1 mM sodium orthovanadate, 50 mM NaF, 1 mM PMSF, 20 mg/mL aprotinin, 20 mg/mL antipain, 20 mg/mL leupeptin and 10 mg/mL pepstatin A) and incubated on ice for 10 min. Nonidet P-40 was added to a final concentration of 0.2% and the cell suspension was passed through a 26-gauge needle to break open the cells. After centrifugation (12,000 g, in a micro centrifuge) at 4°C for 1 min, supernatants were collected as cytoplasmic extracts, and the pellets (crude nuclei) were resuspended in buffer

www.ommegaonline.org

---

B (20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT), 1 mM sodium orthovanadate, 50 mM NaF and the same protease inhibitors as in buffer A). After incubating for 60 min on ice, insoluble materials were pelleted by centrifugation (15,000 g) at 4°C for 10 min and supernatants were collected as nuclear extracts.

**Assays for NFκB and AP-1 Activation**

Nuclear extracts were obtained, according to Nuclear Extraction Kit User Manual, Panomics, Inc. Briefly, confluent cells in 10-cm-diameter dishes were resuspended in 200 μL of buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 1 mM DTT, 0.5 mM EDTA, 0.5 mM PMSF), and lysed with 12.5 μL of 10% NP-40. The nuclear fractions were harvested by centrifugation at 14,000 g, at 4°C for 2 min. The supernatant was used as the source of the cytosolic proteins. The nuclear pellets were resuspended in 50 μL of extraction buffer (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM DTT, 1 mM PMSF, 1 mM EDTA, 1% NP-40), and then incubated on ice, for 10 min. The nuclear debris was removed by centrifugation at 14,000 g at 4°C for 10 min, and the supernatant was used as the source of the nuclear proteins. The activation and subsequent translocation of NFκB and AP-1 to the nucleus was determined by measuring NF-κB and AP-1 protein levels in the nuclear extracts, by Western blot analysis.

**Western Blot Analysis**

Western blot analysis was performed as described previously[8]. Proteins were separated using SDS-PAGE and electrophoretically transferred to a NC membrane (Pall, New York, NY, USA). After that, the membranes were blocked with TBST (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 0.1% Tween-20) containing 5% BSA (Sigma, St. Louis, MO, USA) for 2 h. Then the membranes were incubated with primary antibodies against NFκB, p-c-jun, p-c-jun, c-fos, p-c-fos, poly ADP-ribose protein (PARP), and caspase-3 protein diluted at 1:1000 at 4 °C over night. After washing with TBST for three times, the membranes were incubated with goat anti-rabbit IgG labeled with horse radish peroxidase (Santa Cruz, Dallas, TX, USA) diluted at 1:2000 at room temperature for 2 h. Blots were developed using an ECL plus kit (Amersham Bioscience, Aylesbury, UK), exposed to Kodak auto radiographic films and quantified using Image J software.

**Statistical Analysis**

The results are expressed as mean ± standard deviation (SD), and ANOVA was conducted by using the SPSS software (version 12.0; SPSS, Chicago, IL, USA). When a significant F ratio was obtained (p < 0.05) a post hoc analysis was conducted between groups by using a multiple comparison procedure with a Dunnett’s test. Statistical significance was accepted at a level of p < 0.05.

**Results**

**HPLC Chromatograms and UV Spectra of EAPC and Emodin**

Figure 1 shows that the identification of the bioactive compounds of EAPC was conducted by HPLC as compared to their retention times and characteristic spectra with an authentic standard. The major compounds detected in EAPC were piceid, resveratrol, anthglycoside B, and emodin. By calculating from the standard curves of piceid, resveratrol, anthglycoside B, and emodin, the content of piceid, resveratrol, anthglycoside B, and emodin are 97, 50, 147, 231 mg/g of EAPC, respectively. Apparently, emodin is the main constituent present in EAPC. This result is in agreement with our previous study[5] which showed that emodin is a major compound present in *Polygonum cuspidatum* root. Therefore, emodin was selected as a reference compound for the following tests.

**Effects of EAPC and emodin on cell viability and apoptosis in HT-29 Cell**

The cytotoxicity of HT-29 cell growth after 72 h treatment with different concentrations of EAPC and emodin was determined by MTT assay. The data in Figure 2 show that EAPC and emodin inhibit proliferation of HT-29 cells in a time and concentration dependent manner. The concentration of EAPC and emodin that induced a 50% inhibition (IC50) of HT-29 cell growth as compared to controls was 141.4 and 73.0 μg/mL, respectively. Given that EAPC and emodin are potent inhibitors of HT-29 cell growth, we further examined whether EAPC and emodin induce apoptosis in HT-29 cells. The apoptosis induced by EAPC and emodin on HT-29 cells was determined by flow cytometry as shown in Figure 3. The data show the effect of EAPC and emodin on apoptosis in HT-29 cells, revealing dose results showing a dose-dependent increase in apoptosis in EAPC- and emodin-treated cells. For example, under treatment with 25, 50, 100 μg/mL of emodin for 12 h, the percentages of early apoptosis cells plus the late apoptosis were 2.50, 53.41 and 92.94%, respectively. For EAPC, the percentages of early apoptosis cells plus the late apoptosis were 0.45, 0.49, 0.78, 5.38, and 22.57% for 25, 50, 100, 200 and 400 μg/mL, respectively. These results show a significant increase in apoptosis and decrease in survival in HT-29 cells exposed to EAPC and emodin.

**Figure 2**: Effects of EAPC (A) and Emodin (B) on HT-29 Cells Viability. HT-29 Cells (5 × 104 cells/mL) were treated with test samples.

**Note**: Cell numbers and viability were monitored by MTT assay after 72 h of treatment. Experiments were done in triplicates. Values are expressed as the mean ± SD. Dennett’s test for multiple comparison, *p < 0.05 vs 0 (μg/mL).
Genotoxicity of EAPC and emodin on DNA strand breakage in HT-29 Cell

The comet assay is widely used for measuring DNA strand breaks in eukaryotic cells. In order to understand the genotoxicity of EAPC and emodin on HT-29, comet assay, which is a sensitive technique for measuring DNA strand breaks in eukaryotic cells, was used to determine the damaging effect of EAPC and emodin on DNA. Figure 4 shows that treatment with EAPC and emodin ranged from 25-400 and 25-100 μg/mL, respectively, for 24 h incubation significantly increased damage to the DNA strand, compared to the control cells. When HT-29 cells were incubated with 200 μg/mL of EAPC, DNA damage increased, with a value of 75.6% above that in control cells. Treatment of HT-29 cells with 100 μg/mL of emodin for 24 h induced an increment of 67.8% with respect to the control. These results indicate that EAPC and emodin caused a pronounced damage to HT-29 cells under the tested concentrations. Obviously, EAPC and emodin exerted genotoxicity on HT-29 cells under the tested concentrations.

Figure 4: Genotoxicity of EAPC (A) and Emodin (B) on DNA Strand Breakage in Treated HT-29 Cells (1 ×10⁶ cells/mL) for 24 h.

Note: Tail moment = percent of DNA in the tail × tail length (μm). Experiments were done in triplicates. Values are expressed as the mean ± SD. Dennett’s test for multiple comparison, * p < 0.05 vs 0 (μg/mL).

EAPC and Emodin Induce ROS Accumulation in HT-29 Cell

Increased apoptosis and DNA damage are often associated with ROS accumulation, which can be detected by the ROS-sensitive fluorescence dye, H₂DCFDA. In addition, ROS production is implicated in apoptosis and has been described as an early event. Thus, HT-29 cells were co-incubated with EAPC and emodin for only 6 h before determination of ROS accumulation in HT-29 cells. Figure 5 shows the effect of EAPC and emodin on inducing ROS accumulation in HT-29 cells. The treatment of HT-29 cells with emodin in a range of 25-100 μg/mL for 6 h led to increased ROS accumulation in a concentration-dependent manner, whereas a mild increase in ROS accumulation was observed after the addition of EAPC at 25-400 μg/mL, indicating that EAPC and emodin induce ROS accumulation in HT-29 cells at the tested concentration.

Figure 5: EAPC (A) and Emodin (B)Induces Production of ROS in HT-29 Cells (5 ×10⁴ cells/mL)for 12 h.

Note: Experiments were done in triplicates. Values are expressed as the mean ± SD. Dennett’s test for multiple comparison, * p < 0.05 vs 0 (μg/mL).

Effect of EAPC and Emodin on Caspase-3 and PARP Expression in HT-29 Cell

Caspases are a family of cysteine proteases that play an important role in apoptosis. In addition, activation of caspase-3 results in the degradation of the downstream protein, poly ADP-ribose protein (PARP), a hallmark of apoptosis. To further investigate whether EAPC and emodin affect apoptosis in HT-29 cells, through activation of a caspase pathway, this study identifies caspase-3 activation and PARP protein expression as markers of apoptosis. The results show that treating HT-29 cells with different concentrations of EAPC and emodin did not display any effects on activation of caspase-3 and PARP cleavage (data not shown), suggesting that the cytotoxic effects of EAPC and emodin on HT-29 cells by inducing apoptosis are not associated with activation of a caspase pathway.
Effect of EAPC and emodin on NFκB expression in HT-29 Cell

NFκB is a potent transcriptional factor that regulates the expression of genes that control cell proliferation and cell survival[3]. Therefore, the regulation of NFκB activity by EAPC and emodin is measured by Western blotting in cell nuclear. As shown in Figure 6, emodin treatment decreases the NFκB activity in HT-29 cells; however, EAPC ranging from 25-200 μg/mL does not show any effect on NFκB activity as compared to the control.

Figure 6: Effect of EAPC (A) and Emodin (B) for 12 h on NFκB Expression in HT-29 Cells (5 × 10^4 cells/mL).

---

Effect of EAPC and Emodin on Activator Protein-1 Expression in HT-29 Cell

Activator protein-1 (AP-1), which consists of Jun (c-jun, Jun B, Jun D), Fos (c-fos, Fra-1, fra-2 and Fos B) and Atf (activating transcription factor) sub-families is involved in the regulation of host immune response and plays a major role in the activation of numerous genes involved in cell differentiation, proliferation, apoptosis, immune responses, etc[9]. To assess whether the antiproliferative effects of EAPC and emodin on HT-29 cells are related to AP-1, the activation of AP-1 was measured. According to the results in Figure 7, the phosphorylated levels of c-jun and c-fos increased with increasing concentrations of emodin, however, EAPC did not affect c-jun and c-fos as compared to the control. These observations imply that emodin induced an increase in the nuclear c-jun and c-fos levels, which could be related to the results of AP-1 DNA binding activity[10].

Figure 7: Effect of EAPC (A) and Emodin (B) for 6 h on Activator Protein-1 (AP-1) Expression in HT-29 Cells (5 × 10^4 cells/mL).

---

Discussion

Chemoprevention is defined as the use of agents to inhibit, reverse or retard carcinogenesis[11]. Most chemopreventive agents, derived from natural products, are plant extracts subdivided into blocking agents, which retard or inhibit the initiation step, and suppressing agents, which suppress malignant cell proliferation during the promotion and progression steps of carcinogenesis[12]. According to the data from Figure 2(A), EAPC significantly inhibited HT-29 cell growth. Of special note, emodin, ubiquitously present in plants, which was isolated as a major compound from EAPC, demonstrated effective cytotoxic effect on HT-29 cell growth. Clearly, EAPC and emodin demonstrated antiproliferative activity on HT-29 cells; however, the molecular mechanisms of EAPC and emodin which induced apoptosis have not been elucidated. Therefore, subsequent experiments were conducted.

Externalization of plasma membrane phosphatidylserine is one indicator of apoptosis. Therefore, cytofluorimetric analysis of annexin V-FITC/PI double labeled HT-29 cells was conducted to analyze phosphatidylserine externalization, which
is an event occurring in the early phase of apoptotic cell death when a cell membrane is damaged\(^{[19]}\). The dot plot of flow cytometric data represents each stage of the treated cell line, including viable (V\(^{-}\)), early-stage apoptosis (V\(^{+}\)), late-stage apoptosis (V\(^{-}\)P\(^{-}\)) and necrosis (V\(^{-}\)P\(^{+}\))\(^{[14]}\). For the untreated cells, 99.54\% were viable; however, the percentage of total apoptotic cells in EAPC and emodin increased in a dose-dependent manner (ranging from 0.45 to 22.57 \% and 2.5\% to 92.94\%, respectively), confirming that the mode of cell death was apoptosis. It is worth noting that after 12 h exposure the number of early apoptotic cells decreased, but with significant migration of cells to the late stage of apoptosis. Obviously, EAPC and emodin at tested concentrations induced more late-stage apoptosis than the induction of early-stage apoptosis. This finding indicates that EAPC and emodin allowed the translocation of phosphatidylserine to occur and hence induced apoptotic induction in HT-29 cells\(^{[15]}\). These results show that the annexin V/PI double staining assay confirmed that EAPC and emodin induced apoptosis in HT-29 cells.

Many techniques have been investigated to measure DNA damage, either by measurement of lesions or at the genomic, transcriptomic and enzymatic levels\(^{[16]}\). Among these, the comet assay is widely used as an index of the extent of DNA damage. According to the results from Figure 4, EAPC and emodin have the potential to induce DNA strand breaks in HT-29 cells, which may correspond either to direct DNA damage or to the induction of non-specific endonuclease activity\(^{[14]}\). Many studies have shown that fragmentation of DNA is an event that characterizes apoptosis\(^{[17]}\). Therefore, our data show that the DNA strand breaks observed in HT-29 cells exposed to EAPC and emodin might be linked to apoptosis of HT-29 cells.

ROS are well known as mediators of the apoptosis signaling pathway. Higher levels of ROS in cells induce not only cell death, but also lead to DNA damage and genomic instability\(^{[9]}\). In other words, ROS play an important role in the induction of apoptosis. It is therefore necessary to understand whether the effects of EAPC and emodin stimulated ROS generation in HT-29 cells. Many studies have noted that apoptosis can be induced by ROS, leading to pathological cell death\(^{[18]}\). Thus, enhancement of ROS generation causes lipid per oxidation in cell membranes, DNA damage, and a decrease in the mitochondrial trans membrane potential, which can lead to cell death/injury\(^{[18]}\). The present study shows that EAPC and emodin demonstrated pro-oxidant action on HT-29 cells under the tested concentrations, accompanied by increases in ROS, compared to untreated cells. According to the results from Figures 2 and 5, the increase in ROS generation appeared in parallel with the decrease in HT-29 cell growth under treatment with EAPC and emodin. These observations suggest that increased levels of ROS generated by EAPC and emodin during the oxidative stress period are efficiently harmful to HT-29 cells pretreated with EAPC and emodin, leading to cell death/injury. In addition, the results show that the generation of ROS (Figure 5) was enhanced by EAPC and emodin, resulting in DNA damage (Figure 4). This may contribute to DNA instability, and thereby lead to cell death. Many studies have reported that apoptosis induced by polyphenolic-rich extracts is associated with the increase of ROS generation\(^{[19,20]}\). In other words, the generation of ROS is closely linked to apoptosis. Therefore, without direct ROS scavenging, EAPC and emodin demonstrated significant anti-proliferation of HT-29 cells through their pro-oxidant activity and contribution to oxidative stress, which in turn leads to cell death. This result is in agreement with the report of Droge\(^{[21]}\) who noted that chemopreventors induce apoptosis in part with the induction of ROS generation.

Accumulating evidence shows that NF\(\kappa\)B activation is linked with tumor cell transformation and proliferation. As a transcriptional factor, NF\(\kappa\)B often enhances cell growth in human cancer cells\(^{[22]}\). In an inactive state, NF\(\kappa\)B is sequestered and inactivated in cytoplasm by binding to I\(\kappa\)B. Activation of the NF\(\kappa\)B pathway is mediated by the activation of the I\(\kappa\)B kinase complex (IKK), which leads to the phosphorylation and degradation of I\(\kappa\)B, subsequently causing to nuclear translocation of NF\(\kappa\)B and binding to a specific DNA consensus sequence, which results in the transcriptional activation of NF\(\kappa\)B regulated genes involved in antiapoptosis (e. g., Bcl-2 and Bcl-X\(_{L}\)), proliferation (COX-2 and cyclin D1), angiogenesis (e. g., VEGF) and metastasis (e. g., MMP-9\(^{[10]}\)). In other words, NF\(\kappa\)B is a potent transcriptional factor that regulates the expression of genes that control cell proliferation and cell survival\(^{[9]}\). Our results demonstrate that after treating the cells with emodin, the levels of NF\(\kappa\)B reduce, implying that emodin mediates its anticancer activity through the NF\(\kappa\)B pathway\(^{[18]}\). AP-1 has been implicated to play an important role in the regulation of numerous genes involved in the function and development of the immune system, cell differentiation, proliferation, apoptosis, etc. According to the results from Figure 7, emodin induced and enhanced in the nuclear c-Jun levels, which could be related with the results of AP-1 DNA-binding activity\(^{[10]}\). In other words, emodin has a remarkably promotive effect on c-Jun levels, which accounts for its apoptotic responses in HT-29 cells\(^{[22]}\). In this study, NF\(\kappa\)B and AP-1 are investigated as emodin targets because of the crucial role of NF\(\kappa\)B and AP-1 in cell survival and proliferation. The results obtained indicate that emodin inhibited the NF\(\kappa\)B activity and activated AP-1 binding by the inducing of c-jun nuclear translocation, indicating that JNK is an important mediator in emodin induced cell death\(^{[10]}\). Moreover, these results further confirm that emodin is an effective suppressor of the proliferation pathway and an inducer of apoptosis in HT-29 cells.

Emodin, belonging to the group of natural phenolic compounds, is a natural anthraquinone derivative. Traditionally, emodin is widely used as a mild laxative. In addition, many studies have shown that emodin possesses many biological activities, including antioxidant, antibacterial, antiviral, and antifungal properties\(^{[3]}\). Recent reports have noted that emodin has great potential due to anticancer activities against different cancers, including Hela cells, human bronchial epithelial cells and lung squamous carcinoma cells\(^{[23,24]}\). The present work observed the antiproliferative activity of emodin on human colorectal carcinoma HT-29 cells. In addition, EAPC and emodin showed similar trends in their antiproliferative activity in HT-29 cells. Thus, we suggest that emodin is a major compound that inhibits HT-29 cell growth. On the other hand, emodin demonstrated significant induction of ROS accumulation, inhibition of NF\(\kappa\)B, and enhancement of AP-1 activity. However, EAPC showed mild induction of ROS accumulation and no effect on the activity of NF\(\kappa\)B and AP-1. Apart from these findings, based on HPLC analysis there are other peaks present in EAPC, along with emodin,
piceid, resveratrol, and anthrígloside B, suggesting that other uncharacterized bioactive compounds may be present in EAPC. Many studies have reported that flavonoids and phenolic compounds are strong antioxidants under in vitro conditions in the presence of metal ions which can act as pro-oxidants[25]. In addition, whether or not phenolic compounds can react with other components of cell culture, the overall effect on cells, whether antioxidant or pro-oxidative, is strongly dependent on the composition of the medium[25]. In other words, compounds with antioxidant activity may exhibit pro-oxidant behavior under certain conditions[25]. Therefore, we speculate that these bioactive compounds, along with emodin, present in EAPC[27-33] may render effects that could reduce the pro-oxidant action of EAPC by a direct or a synergistic action and are therefore responsible for the effects of EAPC on ROS accumulation and on the activities of NFkB and AP-1.

Conclusions

To our best knowledge, this study is the first to investigate the antiproliferative effects of EAPC on HT-29 cells. The possible mechanism for its effect involves ROS generation after EAPC exposure in HT-29 cells, which create oxidative bursts and lead to apoptosis of HT-29 cells. In addition, emodin enhanced ROS accumulation and exhibited a strong regulation of cell signaling pathways including a down regulation of NFkB and up regulation of AP-1 transcriptional factors, thereby leading to antiproliferation and apoptosis induction. Therefore, the inhibition of HT-29 cell proliferation could be related to the bioactive constituents present in EAPC. This evidence suggests that EAPC and emodin could be considered as therapeutic agents for the treatment of colorectal cancer. However, scientific trials in vivo should be conducted to validate the relevance of these results.

Disclosure Statement

The authors declare no conflicts of interest.

Funding: This work was supported by research grants NSC100-2320-B-041-004-MY3 and MOST 104-2320-B-041-002 from the National Science Council, Taiwan.

References


